Who is sponsoring NCT04006769?

NCT04006769 is sponsored by Xiangya Hospital of Central South University.

What drugs are being tested in NCT04006769?

Interventions in NCT04006769: Entacapone, Imatinib Mesylate.

What condition does NCT04006769 study?

NCT04006769 studies Gastrointestinal Stromal Tumor, Malignant.

Is NCT04006769 still recruiting?

NCT04006769 is currently completed. Last updated 18 October 2023.

Last reviewed 2023-10-18 · How we verify

NCT04006769

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Entacapone Combination With Imatinib for Treatment of GIST

Completed EARLY_PHASE1 Last updated 18 October 2023

What this trial tests

EARLY_PHASE1 trial testing Entacapone in Gastrointestinal Stromal Tumor, Malignant in 5 participants. Completed in 31 August 2022.

Timeline

30 October 2020

Primary endpoint
31 August 2022

31 August 2022

Quick facts

Lead sponsor	Xiangya Hospital of Central South University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	30 October 2020
Primary completion	31 August 2022
Estimated completion	31 August 2022
Sites	1 location across China

Drugs / interventions tested

Entacapone (ENTACAPONE) — full drug profile →
Imatinib Mesylate — full drug profile →

Conditions studied

Gastrointestinal Stromal Tumor, Malignant — all drugs for Gastrointestinal Stromal Tumor, Malignant →

Sponsor

Xiangya Hospital of Central South University

Who can join

18 and older, any sex, with Gastrointestinal Stromal Tumor, Malignant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the combination of entacapone and imatinib in the treatment of gastrointestinal stromal Tumors who have progressed on the setting of at least Imatinib and Sunitinib. 5 participants will be included in this open-label observatory study.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules.
Vallilas C, Sarantis P, Kyriazoglou A, Koustas E, et al · · 2021 · cited 41× · PMID 33419029 · DOI 10.3390/ijms22020493
Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance.
Song J, Yang P, Chen C, Ding W, et al · · 2025 · cited 40× · PMID 40675967 · DOI 10.1038/s41392-025-02266-z
A Comprehensive Survey of Prospective Structure-Based Virtual Screening for Early Drug Discovery in the Past Fifteen Years.
Zhu H, Zhang Y, Li W, Huang N. · · 2022 · cited 35× · PMID 36555602 · DOI 10.3390/ijms232415961
RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy.
Shi JX, Zhang ZC, Yin HZ, Piao XJ, et al · · 2024 · cited 29× · PMID 39342168 · DOI 10.1186/s12943-024-02132-6
Emerging role of m6A methylation modification in ovarian cancer.
Chang LL, Xu XQ, Liu XL, Guo QQ, et al · · 2021 · cited 20× · PMID 34895230 · DOI 10.1186/s12935-021-02371-3
Precision Oncology in Gastrointestinal Stromal Tumors.
Mechahougui H, Michael M, Friedlaender A. · · 2023 · cited 15× · PMID 37232809 · DOI 10.3390/curroncol30050351
Potential therapies targeting nuclear metabolic regulation in cancer.
Chen Y, Xu J, Liu X, Guo L, et al · · 2023 · cited 7× · PMID 38034101 · DOI 10.1002/mco2.421

Verify or expand the search:

Other trials of Entacapone

Trials testing the same drug.

NCT02096601 — A Safety, Tolerability, and Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Diseas · Phase 1 · completed

Other Xiangya Hospital of Central South University trials

Trials by the same sponsor.

NCT07482670 — Efficacy and Safety of Camrelizumab Plus Rivoceranib and Local Therapy for Hepatocellular Carcinoma With Lung Metastases · not yet recruiting
NCT07412223 — Effect of Tegileridine on Postoperative Bowel Function Recovery in Abdominal Surgery · Phase 4 · not yet recruiting
NCT07369960 — Repetitive Transcranial Magnetic Stimulation Combined With Language Training for Language Disorders in Children With Glo · NA · recruiting
NCT07369999 — Effects of Butylphthalide Enhanced With Tenecteplase on Neurological Function in Mild Disabling Acute Ischemic Stroke · Phase 3 · not yet recruiting
NCT07309913 — China Atrial Fibrillation With Complex Metabolic Disorder Cohort Study (CAME Cohort) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04006769 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiangya Hospital of Central South University
Last refreshed: 18 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04006769.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing